Close Menu

NEW YORK (GenomeWeb) – Fluidigm reported after the close of the market on Thursday that its fourth quarter revenues jumped 17 percent year over year driven in large part by its mass cytometry business.

For the three months ended Dec. 31, the South San Francisco, California-based life science research tools firm tallied revenues of $32.3 million compared to $27.7 million a year ago and besting analysts' average estimate of $30.6 million. The company also bested previous guidance of Q4 revenues of $29 million to $32 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics.